CD45: a critical regulator in immune cells to predict severe and non-severe COVID-19 patients

Mingming Jin1,*, Nannan Shi2,*, Meng Wang1,*, Chunzi Shi1,*, Shengjie Lu1,*, Qing Chang3, Shuang Sha3, Yun Lin4, Yingmin Chen3, Hui Zhou3, Kaiyi Liang3, Xuyuan Huang2, Yuxin Shi2, Gang Huang1

1Shanghai Key Laboratory of Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai 201318, China
2Department of Radiology, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China
3Key Laboratory of Molecular Imaging, Jiading Central Hospital, Shanghai University of Medicine and Health Sciences, Shanghai 201800, China
4Department of Infectious Disease, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China
*Co-first authors

Correspondence to: Gang Huang, Yuxin Shi, Xuyuan Huang; email: huanggang@sumhs.edu.cn, shiyuxin@shphc.org.cn, hxy12777@sumhs.edu.cn

Keywords: coronavirus disease 2019 (COVID-19), severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), pneumonia, clinical characteristics, immunopathology

Received: June 24, 2020 Accepted: July 30, 2020 Published: October 16, 2020

ABSTRACT

The ongoing outbreak of COVID-19 has been announced by the World Health Organization as a worldwide public health emergency. The aim of this study was to distinguish between severe and non-severe patients in early diagnosis. The results showed that the mortality of COVID-19 patients increased accompanied by age. Host factors CRP, IL-1β, hs-CRP, IL-8, and IL-6 levels in severe pneumonia patients were higher than in non-severe patients. CD3, CD8, and CD45 counts were decreased in COVID-19 patients. The results of this study suggest that the K-values of CD45 might be useful in distinguishing between severe and non-severe cases. The cut-off value for CD45 was -94.33. The K-values for CD45 in non-severe case were above the cut-off values, indicating a 100% prediction success rate for severe and non-severe cases following SARS-CoV-2 infection. The results confirmed that immune system dysfunction is a potential cause of mortality following COVID-19 infection, particularly for the elderly. CD45 deficiency dysfunction the naïve and memory T lymphocytes which may affects the long-term effectiveness of COVID-19 vaccines. K-values of CD45 might be useful in distinguishing between severe and non-severe cases in the early infection. May be CD45 could increase the diagnostic sensitivity.

INTRODUCTION

The ongoing outbreak of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), commonly referred to as coronavirus disease 2019 (COVID-19), has been announced by the World Health Organization (WHO) as a worldwide public health emergency [1]. More than 190 countries have reported COVID-19 infections and more than three million people are currently infected worldwide. Each country have more than 15,000 people died from COVID-19 including Italy, France, and Spain, and more than 50,000 people have died in the United States since the beginning of 2020. There are currently more than a million people infected in the United States. The continuous increase in the number of infections has led to a global economic depression [2].

COVID-19 pneumonia was first reported in Wuhan, Hubei Province, China, in December 2019, and was
followed by an outbreak across Hubei Province and other areas in the country. In China, through the unremitting efforts of the entire population, COVID-19 infections were under control by early March 2020 [3]. Regardless of where it originated, COVID-19 is a global disaster. China's experience in treating COVID-19 patients may inform how other countries manage this outbreak. For highly suspected patients, the current recommended procedure is for individuals to self-isolate and wait for results from the coronavirus nucleic acid test as well as radiology examination. If an infection is confirmed, the individual should then enter the emergency ward for treatment [4].

According to WHO interim guidance on January 12, 2020, COVID-19 infections are categorized as severe, mild, or asymptomatic, as well as critical (acute respiratory distress syndrome [ARDS], sepsis, septic shock). Severe pneumonia cases are defined as patients with a respiratory rate > 30 breaths/min, severe respiratory distress, or SpO₂ < 90% in room air. Poor prognostic factors include multilobular infiltration on chest imaging, lymphopenia, bacterial co-infection, smoking history, chronic medical conditions such as hypertension, and age > 60 years (MuLBSTA score) [5]. A number of studies have shown that infection immunopathology is important [6]. However, in terms of cellular immune function, how to distinguish between non-severe and severe cases is unclear. Although nucleic acid testing has been applied clinically to identify COVID-19 infection, distinguishing between non-severe and severe COVID-19 pneumonia cases directly affects patient survival and treatment options. Thus, the present study aimed to describe and compare the clinical characteristics of severe and non-severe cases of COVID-19 pneumonia from the Shanghai Public Health Clinical Center Affiliated to Fudan University. The results of this study will help reveal the immune changes caused by COVID-19 infection as well as distinguish between severe and non-severe cases.

RESULTS

Host factors associated with disease severity

As of March 9, 2020, we had 331 confirmed cases of COVID-19 in Shanghai, including 156 females and 175 males. The eldest was 88 years old and the youngest was 18 years old. The results showed that there was no difference in the rate of SARS-CoV-2 infection between the sexes. Some COVID-19 patients presented with different degrees of abnormality in liver function indexes. The serum levels of globulin, total bilirubin (TBIL), alkaline phosphatase, alanine transaminase, standard base deficit, potassium, and sodium in COVID-19 patients were not significantly different between non-severe and severe pneumonia patients. Albumin and total protein levels of most patients were within normal limits (Figure 1). In non-severe COVID-19 patients, total protein, albumin, and sodium levels were not significantly different across different age groups (< 50, 50–60, 60–70, and ≥ 70 years). However, total protein, albumin, and sodium levels were significantly lower in severe COVID-19 patients compared with non-severe COVID-19 patients (decrease of 26.9%, 42.3%, and 42.3%, respectively; Table 1), suggesting an abnormal liver function index in severe COVID-19 patients compared with non-severe COVID-19 patients.

![Figure 1. Albumin expression in COVID-19 patients.](image-url)
Table 1. Clinical characteristics and laboratory results of liver function indexes for COVID-19 patients.

| Age       | <50  | 50–60 | 60–70 | ≥70  | Overall | Severe (N=26) |
|-----------|------|-------|-------|------|---------|---------------|
| N         | (N=159) | (N=58) | (N=65) | (N=23) | (N=305) |               |
| Sex       |       |       |       |       |         |               |
| female    | 69(43.4%) | 27(46.6%) | 39(60.0%) | 15(65%) | 150(49.2%) | 6 (23.1%)      |
| male      | 90(56.6%) | 31(53.4%) | 26(40.0%) | 8(35%)  | 155(50.8%) | 20 (76.9%)     |
| Total protein (g/L) |       |       |       |       |         |               |
| high      | 11(6.9%) | 0(0%)  | 2(3.1%) | 0(0%)  | 13(4.3%) | 0 (0%)        |
| low       | 3(1.9%)  | 3(5.2%) | 2(3.1%) | 2(8.7%) | 10(3.3%) | 7 (26.9%)      |
| normal    | 145(91.2%) | 55(94.8%) | 61(93.8%) | 21(91.3%) | 282(92.5%) | 19 (73.1%)     |
| Albumin (g/L) |       |       |       |       |         |               |
| low       | 4(2.5%)  | 4(6.9%) | 4(6.2%) | 3(13%)  | 15(4.9%) | 11 (42.3%)     |
| normal    | 155(97.5%) | 54(93.1%) | 61(93.8%) | 20(87%)  | 290(95.1%) | 15 (57.7%)     |
| Globulin (g/L) |       |       |       |       |         |               |
| high      | 67(42.1%) | 18(31.0%) | 21(32.3%) | 5(21.7%) | 111(36.4%) | 9 (34.6%)      |
| normal    | 92(57.9%) | 39(67.2%) | 43(66.2%) | 18(78.3%) | 192 (63.0%) | 0 (0%)        |
| low       | 0(0%)    | 1(1.7%) | 1(1.5%) | 0(0%)   | 2(0.7%)  | 17 (65.4%)     |
| TBIL (μmol/L) |       |       |       |       |         |               |
| high      | 2(1.3%)  | 0(0%)  | 4(6.2%) | 1(4.5%) | 7(2.3%)  | 1 (3.8%)      |
| low       | 12(7.5%) | 1(1.7%) | 2(3.1%) | 1(4.5%) | 16(5.2%) | 0 (0%)        |
| normal    | 152(95.6%) | 54(93.1%) | 62(95.4%) | 23(100%) | 291(95.4%) | 22 (84.6%)     |
| ALP (U/L) |         |       |       |       |         |               |
| high      | 1(0.6%)  | 0(0%)  | 0(0%)  | 0(0%)  | 1(0.3%)  | 0 (0%)        |
| low       | 145(91.2%) | 57(98.3%) | 59(90.8%) | 21(91%)  | 182(92.5%) | 25 (96.2%)     |
| ALT (U/L) |         |       |       |       |         |               |
| high      | 30(18.9%) | 13(22.4%) | 6(9.2%)  | 2(8.7%) | 51(16.7%) | 4 (15.4%)      |
| low       | 129(81.1%) | 45(77.6%) | 59(90.8%) | 21(91.3%) | 254(83.3%) | 22 (84.6%)     |
| SBC (mmol/L) |       |       |       |       |         |               |
| high      | 1(0.6%)  | 2(3.4%) | 5(7.7%) | 0(0%)  | 8(2.6%)  | 2 (7.7%)      |
| low       | 13(8.2%) | 6(10.3%) | 2(3.1%) | 5(21.7%) | 26(8.5%) | 4 (15.4%)      |
| normal    | 1(0.6%)  | 0(0%)  | 1(1.5%) | 0(0%)  | 2(0.7%)  | 1(3.8%)       |
| Potassium (mmol/L) |       |       |       |       |         |               |
| low       | 19(11.9%) | 12(20.7%) | 14(21.5%) | 2(8.7%) | 47(15.4%) | 5(19.2%)       |
| N         | 3(1.9%)  | 1(1.7%) | 0(0%)  | 0(0%)  | 5(1.6%)  | 0 (0%)        |
| normal    | 137(86.2%) | 45(77.6%) | 51(78.5%) | 21(91.3%) | 253(83.0%) | 21(80.8%)      |
| Sodium (mmol/L) |       |       |       |       |         |               |
| low       | 3(1.9%)  | 5(8.6%) | 4(6.2%) | 4(17.4%) | 16(5.2%) | 11(42.3%)      |
| N         | 3(1.9%)  | 1(1.7%) | 0(0%)  | 1(4.3%) | 5(1.6%)  | 0 (0%)        |
| normal    | 153(96.2%) | 52(89.7%) | 61(93.8%) | 18(78.3%) | 284(93.1%) | 15(57.7%)      |

TBIL, total bilirubin; ALP, alkaline phosphatase; ALT, alanine transaminase; SBD, standard base deficit.

Urine analysis of uric acid, blood urea nitrogen, urinary red blood cells, urine-pH, and urinary white blood cells showed that these factors were not significantly different between non-severe and severe pneumonia patients. However, urine protein and urine latent blood (BLD) were significantly increased in both non-severe and severe COVID-19 patients. Severe COVID-19 patients showed a greater increase in urine protein and BLD, suggesting kidney damage following SARS-CoV-2 infection (Table 2). Data analysis found that chlorine levels in non-severe patients were significantly increased. Chlorine, the main anion in the extracellular fluid of the human body, regulates the acid-base balance, osmotic pressure, and water distribution. Decreased chlorine levels indicate kidney damage. However, the kidney function indexes of non-severe COVID-19 patients across different age groups (<50, 50–60, 60–70, ≥70 years) were not significantly different (Table 2).
Table 2. Urine test predicts kidney function for COVID-19 patients.

| Age         | Non-severe | Severe |
|-------------|------------|--------|
|             | <50 (N=159) | 50–60 (N=58) | 60–70 (N=65) | ≥70 (N=23) | Overall (N=305) | (N=26) |
| N           |            |        |            |            |                 |        |
| Uric acid (μmmol/L) |            |        |            |            |                 |        |
| high        | 13(8.2%)   | 4(6.9%) | 3(4.6%)   | 4(17.4%)  | 24(7.9%)       | 4(15.4%) |
| low         | 2(1.3%)    | 3(5.2%) | 0(0%)     | 1(4.3%)   | 6(2.0%)        | 4(15.4%) |
| normal      | 144(90.6%) | 51(87.9%) | 62(95.4%) | 18(78.3%) | 275(90.2%)     | 18(69.2%) |
| BUN (mmol/L) |            |        |            |            |                 |        |
| high        | 4(2.5%)    | 3(5.2%) | 9(13.8%)  | 4(17.4%)  | 20(6.6%)       | 7(26.9%) |
| low         | 10(6.6%)   | 0(0%)  | 1(1.5%)   | 0(0%)     | 2(0.7%)        | 0(0%)   |
| normal      | 154(96.9%) | 55(94.8%) | 55(83.6%) | 19(74.2%) | 283(92.8%)     | 19(73.1%) |
| Urine protein |            |        |            |            |                 |        |
| high        | 32(20.1%)  | 18(31.0%) | 19(29.2%) | 6(26%)    | 75(24.6%)      | 16(61.5%) |
| N           | 35(22.0%)  | 10(17.2%) | 11(16.9%) | 3(13%)    | 59(19.3%)      | 3(11.5%) |
| normal      | 92(57.9%)  | 30(51.7%) | 35(38.3%) | 14(61%)   | 171(56.1%)     | 7(26.9%) |
| URBC (cell/μl) |            |        |            |            |                 |        |
| high        | 18(11.3%)  | 6(10.3%) | 6(9.2%)   | 3(13%)    | 33(10.8%)      | 7(26.9%) |
| N           | 36(22.6%)  | 10(17.2%) | 12(18.5%) | 3(13%)    | 61(20.0%)      | 3(11.5%) |
| normal      | 105(66.0%) | 42(72.4%) | 47(72.3%) | 15(74%)   | 211(69.2%)     | 16(61.5%) |
| BLD         |            |        |            |            |                 |        |
| high        | 26(16.4%)  | 15(25.9%) | 12(18.5%) | 5(21.7%)  | 58(19.0%)      | 11(42.3%) |
| N           | 35(22.0%)  | 10(17.2%) | 11(16.9%) | 3(13.1%)  | 59(19.3%)      | 3(11.5%) |
| normal      | 98(61.6%)  | 33(56.9%) | 42(64.6%) | 15(65.2%) | 188(61.6%)     | 12(46.2%) |
| U-pH        |            |        |            |            |                 |        |
| N           | 35(22.0%)  | 10(17.2%) | 11(16.9%) | 3(13%)    | 59(19.3%)      | 2(7.7%)  |
| normal      | 124(78.0%) | 48(82.8%) | 52(80.0%) | 20(87%)   | 244(80.0%)     | 3(11.5%) |
| high        | 0(0%)      | 0(0%)   | 2(3.1%)   | 0(0%)     | 2(0.7%)        | 21(80.8%) |
| UWBC (cell/μl) |            |        |            |            |                 |        |
| N           | 36(22.6%)  | 10(17.2%) | 11(16.9%) | 3(13%)    | 60(19.7%)      | 3(11.5%) |
| normal      | 123(77.4%) | 48(82.8%) | 54(83.1%) | 20(87%)   | 245(80.3%)     | 23(88.5%) |
| Chlorin (mmol/L) |            |        |            |            |                 |        |
| high        | 58(36.5%)  | 21(36.2%) | 26(40.0%) | 9(39.1%)  | 114(37.4%)     | 4(15.4%) |
| N           | 3(1.9%)    | 1(1.7%)  | 0(0%)     | 1(4.3%)   | 5(1.6%)        | 0(0%)   |
| normal      | 98(61.6%)  | 36(62.1%) | 39(60.0%) | 13(56.5%) | 186(61.0%)     | 22(84.6%) |

N, the data is incomplete; BUN, serum urea nitrogen; URBC, urinary red blood cell; BLD, urine latent blood; U-pH, urine-pH; UWBC, urine white blood cell.

Serum inflammatory factor levels of IL-2, IL-1β, IL-4, IL-6, IL-5, IL-10, IL-8, IL-12P70, IL-17, IFN-α, TNF-α, IFN-γ, and endotoxin in COVID-19 patients showed no significant differences between non-severe and severe pneumonia patients. However, IL-6, IL-1β, and IL-8 expression levels in severe pneumonia patients were increased, and the levels of IL-6 showed the greatest increase. The levels of C-reactive protein (CRP) and high-sensitivity C-reactive protein (hs-CRP) were significantly increased in both non-severe and severe pneumonia patients. A higher proportion of the severe pneumonia patient population had increased CRP and hs-CRP levels (Table 3). Severe pneumonia patients showed higher levels of CRP (Figure 2A) and hs-CRP (Figure 2B) in the first 7 days of analysis, suggesting that SARS-CoV-2 has bacterial infection characteristics. Serum inflammatory factor levels of IL-2, IL-1β, IL-5, IL-4, IL-6, IL-8, IL-10, IL-17, IL-12P70, IFN-α, TNF-α, IFN-γ, endotoxin, CRP, and hs-CRP of non-severe COVID-19 patients across different age groups (< 50, 50–60, 60–70, and ≥ 70 years) were not significantly different (Table 3).
Table 3. Inflammatory factors detection for COVID-19 patients.

| Age  | Non-severe | Severe |
|------|------------|--------|
|      | N=159      | N=58   | N=65   | N=23   | N=305 | N=26  |
|      | (N=65)     | (N=23) | (N=305) | (N=26) |
| CRP (mg/L) | | | | | | |
| high | 65 (40.9%) | 40 (69.0%) | 36 (55.4%) | 15 (65.2%) | 156 (51.1%) | 26 (100%) |
| N.A  | 3 (1.9%)  | 1 (1.7%) | 1 (1.5%) | 0 (0%) | 5 (1.6%) | 0 (0%) |
| normal | 91 (57.2%) | 17 (29.3%) | 28 (43.1%) | 8 (34.8%) | 144 (47.2%) | 0 (0%) |
| hs-CRP (mg/L) | | | | | | |
| high | 76 (47.8%) | 39 (67.2%) | 42 (64.6%) | 18 (78.3%) | 175 (57.4%) | 24 (92.3%) |
| N.A  | 3 (1.9%)  | 2 (3.4%) | 1 (1.5%) | 0 (0%) | 7 (2.3%) | 2 (7.7%) |
| normal | 80 (50.3%) | 17 (29.3%) | 22 (33.8%) | 4 (17.4%) | 123 (40.3%) | 0 (0%) |
| IL-1β (pg/ml) | | | | | | |
| high | 23 (14.5%) | 7 (12.1%) | 7 (10.8%) | 1 (4.3%) | 38 (12.5%) | 8 (30.8%) |
| N   | 99 (62.3%) | 31 (53.4%) | 36 (55.4%) | 12 (52.2%) | 178 (58.4%) | 1 (3.8%) |
| normal | 37 (23.3%) | 20 (34.5%) | 22 (33.8%) | 10 (43.5%) | 89 (29.2%) | 17 (65.4%) |
| IL-2 (pg/ml) | | | | | | |
| high | 1 (0.6%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (0.3%) | 3 (11.5%) |
| N   | 61 (38.4%) | 15 (25.9%) | 17 (26.2%) | 6 (26.1%) | 99 (32.5%) | 1 (3.8%) |
| normal | 97 (61.0%) | 43 (74.1%) | 48 (73.8%) | 17 (73.9%) | 205 (67.2%) | 22 (84.6%) |
| IL-4 (pg/ml) | | | | | | |
| N   | 61 (38.4%) | 15 (25.9%) | 17 (26.2%) | 6 (26.1%) | 99 (32.5%) | 1 (3.8%) |
| normal | 98 (61.6%) | 43 (74.1%) | 48 (73.8%) | 17 (73.9%) | 206 (67.5%) | 25 (96.2%) |
| IL-5 (pg/ml) | | | | | | |
| N   | 99 (62.3%) | 31 (53.4%) | 36 (55.4%) | 12 (52.2%) | 178 (58.4%) | 1 (3.8%) |
| normal | 60 (37.7%) | 27 (46.6%) | 29 (44.6%) | 11 (47.8%) | 127 (41.6%) | 21 (80.8%) |
| IL-6 (pg/ml) | | | | | | |
| N   | 61 (38.4%) | 15 (25.9%) | 17 (26.2%) | 6 (26.1%) | 99 (32.5%) | 1 (3.8%) |
| normal | 86 (54.1%) | 31 (53.4%) | 36 (55.4%) | 13 (56.5%) | 166 (54.4%) | 9 (34.6%) |
| IL-8 (pg/ml) | | | | | | |
| N   | 99 (62.3%) | 31 (53.4%) | 36 (55.4%) | 12 (52.2%) | 178 (58.4%) | 1 (3.8%) |
| normal | 57 (35.8%) | 27 (46.6%) | 28 (43.1%) | 11 (47.8%) | 123 (40.3%) | 16 (61.5%) |
| IL-10 (pg/ml) | | | | | | |
| N   | 61 (38.4%) | 15 (25.9%) | 17 (26.2%) | 6 (26.1%) | 99 (32.5%) | 3 (11.5%) |
| normal | 98 (61.6%) | 43 (74.1%) | 48 (73.8%) | 17 (73.9%) | 204 (66.9%) | 1 (3.8%) |
| IL-12P70 (pg/ml) | | | | | | |
| N   | 99 (62.3%) | 31 (53.4%) | 36 (55.4%) | 12 (52.2%) | 178 (58.4%) | 1 (3.8%) |
| normal | 58 (36.5%) | 26 (44.8%) | 29 (44.6%) | 11 (47.8%) | 124 (40.7%) | 24 (92.3%) |
| IL-17 (pg/ml) | | | | | | |
| N   | 61 (38.4%) | 15 (25.9%) | 17 (26.2%) | 6 (26.1%) | 99 (32.5%) | 1 (3.8%) |
| normal | 98 (61.6%) | 43 (74.1%) | 48 (73.8%) | 17 (73.9%) | 206 (67.5%) | 24 (92.3%) |
| TNF-α (pg/ml) | | | | | | |
| high | 2 (1.3%) | 1 (1.7%) | 0 (0%) | 0 (0%) | 3 (1.0%) | 1 (3.8%) |
| N   | 61 (38.4%) | 15 (25.9%) | 18 (27.7%) | 6 (26.1%) | 100 (32.8%) | 1 (3.8%) |
| normal | 96 (60.4%) | 43 (74.1%) | 47 (72.3%) | 17 (73.9%) | 203 (66.6%) | 25 (96.2%) |
| IFN-α (pg/ml) | | | | | | |
| N   | 99 (62.3%) | 31 (53.4%) | 37 (56.9%) | 12 (52.2%) | 179 (58.7%) | 3 (11.5%) |
| normal | 60 (37.7%) | 27 (46.6%) | 28 (43.1%) | 11 (47.8%) | 126 (41.3%) | 23 (88.5%) |
Cell subsets and immunoglobulin detection in COVID-19 patients

Routine blood tests showed that the following characteristics were significantly different between non-severe and severe pneumonia patients: red blood cells; hemoglobin; white blood cells (WBCs); basophil count; basophil percentage; monocyte and neutrophil count; CD4, CD8, CD4/CD8, CD9, and CD16/CD56 count/percentage; immunoglobulin A (IgA); and IgM. Eosinophil count/percentage, lymphocyte count/percentage, CD3 count/percentage, monocyte percentage, and CD45 count were decreased after SARS-CoV-2 infection. Severe pneumonia patients had lower CD3 (Figure 3A), monocyte, CD8 (Figure 3B), and CD45 (Figure 3C) counts in the first 7 days of analysis compared with non-severe patients. Different age group analysis found that lymphocyte, CD3, CD8, and CD45 counts were decreased in older SARS-CoV-2 patients, suggesting that immune function deteriorates with increasing age. The neutrophil percentage was also increased following SARS-CoV-2 infection, indicating that inflammatory infections are more severe (Table 4).

Analysis of the levels of CD3 (Figure 4A), CD8 (Figure 4B), and CD45 (Figure 4C) levels in the first 3 days of analysis showed that CD3 and CD45 were more significantly decreased in severe cases compared with non-severe cases. The K-values for CD3 and CD45 in severe cases were -85 and -178.5, respectively, while...
Table 4. Cell subsets and immunoglobulin detection for COVID-19 patients.

| Age      | <50 (N=159) | 50–60 (N=58) | 60–70 (N=65) | ≥70 (N=23) | Overall (N=305) | Severe (N=26) |
|----------|-------------|--------------|--------------|-----------|-----------------|---------------|
| Hemoglobin (g/L) |            |              |              |           |                 |               |
| high     | 46(28.9%)   | 13(22.4%)    | 1(1.5%)      | 10(0%)    | 61(20.0%)       | 5(19.2%)      |
| low      | 63(38.8%)   | 4(6.9%)      | 7(10.8%)     | 3(0%)     | 20(6.6%)        | 3(11.5%)      |
| normal   | 107(67.3%)  | 41(70.7%)    | 57(87.7%)    | 19(100%)  | 224(73.4%)      | 18(69.2%)     |
| RBC (×10^12/L) |            |              |              |           |                 |               |
| high     | 42(26.4%)   | 4(6.9%)      | 1(1.5%)      | 10(0%)    | 48(15.7%)       | 5(19.2%)      |
| low      | 5(3.1%)     | 6(10.3%)     | 11(16.9%)    | 7(50.0%)  | 29(9.5%)        | 4(15.4%)      |
| normal   | 112(70.4%)  | 48(82.8%)    | 53(81.5%)    | 15(50.0%) | 228(74.8%)      | 17(65.4%)     |
| WBC (×10^9/L) |            |              |              |           |                 |               |
| high     | 4(2.5%)     | 0(0%)        | 1(1.5%)      | 0(0%)     | 5(1.6%)         | 5(19.2%)      |
| low      | 37(23.3%)   | 14(24.1%)    | 16(24.6%)    | 9(0%)     | 76(24.9%)       | 7(26.9%)      |
| normal   | 118(74.2%)  | 44(75.9%)    | 48(73.8%)    | 14(100%)  | 224(73.4%)      | 14(53.8%)     |
| Basophil (×10^9/L) |          |              |              |           |                 |               |
| normal   | 159(100%)   | 58(100%)     | 65(100%)     | 23(100%)  | 305(100%)       | 25(96.2%)     |
| high     | 0(0%)       | 0(0%)        | 0(0%)        | 0(0%)     | 0(0%)           | 1(3.8%)       |
| Eosinophil (×10^9/L) |       |              |              |           |                 |               |
| normal   | 90(56.6%)   | 37(63.8%)    | 46(70.8%)    | 19(50%)   | 192(63.0%)      | 23(88.5%)     |
| high     | 69(43.4%)   | 21(36.2%)    | 19(29.2%)    | 4(50%)    | 113(37.0%)      | 3(11.5%)      |
| Lymphocyte (×10^9/L) |          |              |              |           |                 |               |
| high     | 10(0.6%)    | 0(0%)        | 0(0%)        | 0(0%)     | 1(0.3%)         | 1(3.8%)       |
| low      | 27(17.0%)   | 13(22.4%)    | 18(27.7%)    | 7(50.0%)  | 65(21.3%)       | 15(57.7%)     |
| normal   | 131(82.4%)  | 45(77.6%)    | 47(72.3%)    | 16(50.0%) | 239(78.4%)      | 10(38.5%)     |
| Lymphocyte percentage (%) |          |              |              |           |                 |               |
| high     | 16(10.1%)   | 2(3.4%)      | 2(3.1%)      | 0(0%)     | 20(6.6%)        | 1(3.8%)       |
| low      | 36(22.6%)   | 18(31.0%)    | 24(36.9%)    | 9(50%)    | 87(28.5%)       | 19(73.1%)     |
| normal   | 107(67.3%)  | 38(65.5%)    | 39(60.0%)    | 14(50%)   | 198(64.9%)      | 6(23.1%)      |
| Monocyte (×10^9/L) |         |              |              |           |                 |               |
| high     | 8(5.0%)     | 4(6.9%)      | 3(4.6%)      | 1(0%)     | 16(5.2%)        | 4(15.4%)      |
| normal   | 151(95.0%)  | 54(93.1%)    | 62(95.4%)    | 22(100%)  | 289(94.8%)      | 22(84.6%)     |
| Monocyte percentage (%) |          |              |              |           |                 |               |
| high     | 90(56.6%)   | 37(63.8%)    | 41(63.1%)    | 17(100%)  | 185(60.7%)      | 8(30.8%)      |
| low      | 2(1.3%)     | 0(0%)        | 0(0%)        | 0(0%)     | 2(0.7%)         | 4(15.4%)      |
| normal   | 67(42.1%)   | 21(36.2%)    | 24(36.9%)    | 6(0%)     | 118(38.7%)      | 14(53.8%)     |
| Neutrophil (×10^9/L) |         |              |              |           |                 |               |
| high     | 3(1.9%)     | 0(0%)        | 1(1.5%)      | 0(0%)     | 4(1.3%)         | 4(15.4%)      |
| low      | 50(31.4%)   | 15(25.9%)    | 17(26.2%)    | 7(0%)     | 89(29.2%)       | 5(19.2%)      |
| normal   | 106(66.7%)  | 43(74.1%)    | 47(72.3%)    | 16(100%)  | 212(69.5%)      | 17(65.4%)     |
| Neutrophil percentage (%) |        |              |              |           |                 |               |
| high     | 38(23.9%)   | 21(36.2%)    | 20(30.8%)    | 11(50.0%) | 90(29.5%)       | 19(73.1%)     |
| low      | 22(13.8%)   | 6(10.3%)     | 2(3.1%)      | 2(0%)     | 32(10.5%)       | 13(8.8%)      |
| normal   | 99(62.3%)   | 31(53.4%)    | 43(66.2%)    | 10(50.0%) | 183(60.0%)      | 6(23.1%)      |
| CD45 count (cell/μl) |        |              |              |           |                 |               |
| high     | 1(0.6%)     | 1(1.7%)      | 1(1.5%)      | 0(0%)     | 3(1.0%)         | 0(0%)         |
| low      | 18(11.3%)   | 11(19.0%)    | 13(20.0%)    | 7(50.0%)  | 49(16.1%)       | 15(57.7%)     |
| normal   | 2(1.3%)     | 0(0%)        | 0(0%)        | 0(0%)     | 2(0.7%)         | 0(0%)         |
| CD3 count (cell/μl) |        |              |              |           |                 |               |
| high     | 138(86.8%)  | 46(79.3%)    | 51(78.5%)    | 15(50.0%) | 251(82.3%)      | 11(42.3%)     |
|                | high        | low         | N           | normal     |
|----------------|-------------|-------------|-------------|------------|
| **CD3 percentage (%)** |             |             |             |            |
| high           | 6(3.8%)     | 2(3.4%)     | 0(0%)       | 10(3.3%)   |
| low            | 3(1.9%)     | 2(3.4%)     | 0(0%)       | 9(3.0%)    |
| N              | 2(1.3%)     | 0(0%)       | 0(0%)       | 2(0.7%)    |
| normal         | 148(93.1%)  | 54(93.1%)   | 60(92.3%)   | 284(93.1%) |
| **CD4 count (cell/μl)** |             |             |             |            |
| low            | 9(5.7%)     | 14(24.1%)   | 17(26.2%)   | 51(16.7%)  |
| N              | 2(1.3%)     | 0(0%)       | 0(0%)       | 2(0.7%)    |
| normal         | 148(93.1%)  | 44(75.9%)   | 48(73.8%)   | 252(82.6%) |
| **CD4 percentage (%)** |             |             |             |            |
| high           | 4(2.5%)     | 1(1.7%)     | 1(1.5%)     | 10(3%)     |
| low            | 1(0.6%)     | 2(3.4%)     | 7(10.8%)    | 13(4.3%)   |
| N              | 2(1.3%)     | 0(0%)       | 0(0%)       | 2(0.7%)    |
| normal         | 152(95.6%)  | 55(94.8%)   | 57(87.7%)   | 283(92.8%) |
| **CD4/CD8**    |             |             |             |            |
| high           | 10(6.6%)    | 6(10.3%)    | 7(10.8%)    | 17(5.6%)   |
| low            | 9(5.7%)     | 1(1.7%)     | 3(4.6%)     | 14(4.6%)   |
| N              | 2(1.3%)     | 0(0%)       | 0(0%)       | 2(0.7%)    |
| normal         | 147(92.5%)  | 51(87.9%)   | 55(84.6%)   | 272(89.2%) |
| **CD9 count (cell/μl)** |             |             |             |            |
| high           | 31(19.5%)   | 6(10.3%)    | 8(12.3%)    | 45(14.8%)  |
| low            | 2(1.3%)     | 1(1.7%)     | 4(6.2%)     | 12(3.9%)   |
| N              | 66(41.5%)   | 17(29.3%)   | 20(30.8%)   | 109(35.7%) |
| normal         | 66(37.7%)   | 34(58.6%)   | 33(50.8%)   | 139(45.6%) |
| **CD9 percentage (%)** |             |             |             |            |
| high           | 2(1.3%)     | 2(3.4%)     | 1(1.5%)     | 8(2.6%)    |
| low            | 1(0.6%)     | 0(0%)       | 1(1.5%)     | 6(2.0%)    |
| N              | 66(41.5%)   | 17(29.3%)   | 20(30.8%)   | 109(35.7%) |
| normal         | 90(56.6%)   | 39(67.2%)   | 43(66.2%)   | 182(59.7%) |
| **CD6CD56 count (cell/μl)** |             |             |             |            |
| high           | 4(2.5%)     | 1(1.7%)     | 4(6.2%)     | 9(3.0%)    |
| low            | 11(6.9%)    | 5(8.6%)     | 5(7.7%)     | 24(7.9%)   |
| N              | 66(41.5%)   | 17(29.3%)   | 20(30.8%)   | 109(35.7%) |
| normal         | 78(49.1%)   | 35(60.3%)   | 36(55.4%)   | 163(53.4%) |
| **CD6CD56 percentage (%)** |             |             |             |            |
| high           | 2(1.3%)     | 0(0%)       | 4(6.2%)     | 7(2.3%)    |
| low            | 9(5.7%)     | 1(1.7%)     | 1(1.5%)     | 13(4.3%)   |
| N              | 66(41.5%)   | 17(29.3%)   | 20(30.8%)   | 109(35.7%) |
| normal         | 82(51.6%)   | 40(69.0%)   | 40(61.5%)   | 176(57.7%) |
| **IgA (g/L)**  |             |             |             |            |
| high           | 13(8.2%)    | 9(15.5%)    | 9(13.8%)    | 31(10.2%)  |
| N              | 3(1.9%)     | 2(3.4%)     | 1(1.5%)     | 6(2.0%)    |
| normal         | 143(89.9%)  | 47(81.0%)   | 55(84.6%)   | 268(87.9%) |
| **IgM (g/L)**  |             |             |             |            |
| high           | 4(2.5%)     | 1(1.7%)     | 1(1.5%)     | 6(2.0%)    |
| low            | 11(6.9%)    | 10(17.2%)   | 16(24.6%)   | 47(15.4%)  |
| N              | 3(1.9%)     | 2(3.4%)     | 1(1.5%)     | 6(2.0%)    |
| normal         | 141(88.7%)  | 45(77.6%)   | 47(72.3%)   | 246(80.7%) |

RBC, red blood cell; WBC, white blood cell.
the K-values for CD3 and CD45 in non-severe cases were -13.4 and -19.2, respectively. Thus, the change in K-value was most significant in the severe group, especially for CD3 (-85) and CD45 (-178.5). The analysis found that cut-off values for CD3 and CD45 were -66.7 and -94.33, respectively. A clinical test, using 80 COVID-19 patients for backward verification, revealed that the K-values for both CD3 and CD45 in non-severe cases were above the cut-off values, indicating a 100% prediction success rate for severe and non-severe cases following SARS-CoV-2 infection (Figure 5).

**DISCUSSION**

The novel coronavirus SARS-CoV-2 possesses approximately 80% of the genetic sequence of SARS-CoV [7, 8]. COVID-19 is a self-limiting disease, which has also developed into a fatal disease. Respiratory droplets, close contact, aerosol, and fecal transmission are now regarded to be the primary routes of transmission [9–11]. The rapid spread of globalization has turned the disease into a global disaster. COVID-19 has caused millions of infections and hundreds of thousands of deaths. Thus, analysis of clinical case information is important in the control, prevention, and treatment of the virus.

The risk factors relevant to COVID-19 development and progression from initial infection to death included older age, inflammatory response, and immune dysfunction, consistent with previous reports [12]. The present study analyzed the clinical data of 331 COVID-19 patients. The data showed that individuals of older age (> 60 years old) were more susceptible to SARS-CoV-2 infection, consistent with previous reports [13]. The elderly are often associated with chronic diseases such as diabetes, hypertension, and coronary heart disease, and are more vulnerable. Our
analysis found that the risks associated with COVID-19 increased with increasing age. The immune system weakens with increasing age; therefore, increased age is associated with a greater risk of COVID-19 infection and death, likely due to a less rigorous immune response.

Analysis of inflammatory cytokines revealed that CRP, hs-CRP, IL-1β, IL-8, IL-10, and IL-6 expression levels were increased in severe pneumonia patients, and a higher proportion of the severe pneumonia population exhibited increased levels of CRP (100%), hs-CRP (92.3%), IL-6 (61.5%), and IL-10 (84.6%) compared with non-severe patients. Although IL-10 has anti-inflammatory properties, it cannot reverse the inflammatory storm induced by COVID-19. Immunocytoanalysis found that WBCs and neutrophils were also increased, indicating an inflammatory response. Our study was consistent with previous studies which found that, in early stage COVID-19 infection, CRP levels are positively correlated to lung lesions, which could reflect disease severity [14–16]. This early increase in serum levels of pro-inflammatory cytokines was observed in SARS-CoV and Middle East Respiratory Syndrome (MERS)-CoV infection, suggesting similar cytokine storm-mediated disease severity [17, 18]. Cytokines are crucial mediators of the inflammatory response; previous reports have indicated that cytokine storm syndrome occurs with SARS-CoV-2 infection [19, 20]. This cytokine storm can initiate viral sepsis and inflammatory-induced lung injury, which can result in other complications such as pneumonitis, ARDS, shock, respiratory failure, organ failure, and death.

A number of studies have found that immune system disorders are a key factor in “cytokine storms”. Immune cell analysis found that CD3, CD45, and CD8 counts were decreased in SARS-CoV-2 infection patients. A higher proportion of severe pneumonia cases exhibited decreased CD3 (69.2%), CD45 (57.7%), and CD8 (50%) compared with non-severe patients. The first 7 days of analysis showed that severe COVID-19 patients had lower levels of CD3, CD8, and CD45. A decreased CD3 count indicates a reduction in total T cells. We also found that the lymphocyte count/percentage decreased and a higher proportion of the severe pneumonia patient population exhibited a decrease in lymphocytes (57.7%), suggesting that the immune system is damaged after SARS-CoV-2 infection. Decreased levels of CD8 indicate T-cell exhaustion, similar to hepatitis B virus (HBV) infection. It is known that HBV-specific T cells play an important role in antiviral protection and failure to control HBV is related to a dysfunctional T cell response [21]. In this manner, it is important to increase the immunity of COVID-19 patients. The present study found that CD45 counts were decreased; CD45 is necessary for T cell activation. CD45 deficiency results in B- and T-lymphocyte dysfunction in the form of severe combined immune deficiency. CD45 plays an important role in autoimmune traits and cancer as well as in infectious diseases including fungal and virus infections [22, 23]. CD45 has been shown to be decreased in density on the T cell surface during HIV infection [24]. CD45 is a transmembrane phosphatase that functions in T cell activation and signaling. Multiple CD45 isoforms are simultaneously expressed on T cells due to alternative splicing of three exons that correspond to extracellular domains A, B, and C or the exclusion of all three (CD45RO). A number of studies have reported that higher avidity CD8+ T cell responses are desirable in vaccine responses to pathogens and cancer, whereas the immunity persistence generated following vaccination is a factor for many pathogens. Maintaining high CD45RB expression status is indispensable for maximizing pathogen-specific immunity longevity [25–27]. This further suggests that SARS-CoV-2 can be aggressive to the immune system. Thus, a reduced level of CD45 may be a useful standard for the diagnosis of severe patients from non-severe patients.

Further analysis showed that albumin levels were decreased in COVID-19 patients, indicating hypoimmunity following SARS-CoV-2 infection [28, 29]. Dysfunction of the immune system can result in the accumulation of inflammatory factors. The inflammatory microenvironment can destroy the acid-base balance, osmotic pressure, and water distribution (decreased chlorine and increased urine protein), ultimately leading to liver and kidney damage. Multiple organ damage is a common cause of death of elderly patients infected with SARS-CoV-2 [30, 31]. The target for immune function may be the key to treatment of this disease.

How changes in immune cell number can be used to distinguish between severe and non-severe patients has important clinical significance. After analyzing the results of CD3, CD8, and CD45 levels in the first 3 days, it was found that the K-value change was the most significant in the severe group, especially for CD3 (-85) and CD45 (-178.5). The analysis found that cut-off values for CD3 and CD45 were -66.7 and -94.33, respectively. Clinical test found that the K-values for both CD3 and CD45 in non-severe case were on the up of the cut-off values, indicating a 100% prediction success rate for severe and non-severe cases following SARS-CoV-2 infection. It is likely that CD45 is more clinically meaningful to distinguish severe SARS-CoV-2 cases from non-severe cases. We believe that this standard will aid in the clinical assessment of non-
severe and severe patients. Due to the limited sample size of SARS-CoV-2 cases, large sample collection will be needed in future studies for the precise prediction of severe and non-severe cases following SARS-CoV-2 infection.

CONCLUSIONS

In conclusion, the current data suggest that immune system damage may be the pathogenic feature of COVID-19. We believe that the findings described here are essential to understand the clinical characteristics of this virus, and verify that immune system dysfunction is a cause of death following infection, particularly for elderly patients. The study also found that the K-values of CD3 and CD45 might be useful to distinguish between severe and non-severe cases. Overall, we believe that the results of the present study will help distinguish between non-severe and severe patients clinically.

MATERIALS AND METHODS

Patients and data collection

We conducted analysis of 311 COVID-19 patients from the Shanghai Public Health Clinical Center Affiliated to Fudan University in Shanghai, China (YJ-2020-S035-01). COVID-19 infections diagnosed from January 27, 2020 to March 9, 2020 were included. We diagnosed COVID-19 based on criteria issued by the National Health Commission of China. We divided patients into non-severe (n = 305) and severe (n = 26) cases according to the “China National Health Commission, Diagnosis and treatment of pneumonia caused by new coronavirus infection”. We obtained basic information from the electronic medical record system. Patient information such as clinical and laboratory data were extracted and used for analysis. The Ethics Committee of Shanghai Public Health Clinical Center Affiliated to Fudan University approved the study and written informed consent was obtained from all subjects.

Following the guidelines for diagnosis and treatment of novel coronavirus (2019-nCoV) infection by the National Health Commission, at the time of hospitalization, patients with either a respiratory rate > 30 breaths/min, SpO2 < 93% in room air, or PaO2/FiO2 ≤ 300 mmHg, were categorized as severe cases, and others were defined as non-severe cases.

Statistical analysis

We expressed continuous data as mean ± standard deviation. We summarized categorical variables as counts and percentages in each category. We employed t-tests for continuous variables. We used Fisher’s exact test for categorical variables as appropriate. The Wilcoxon signed-rank test was used for K-value analysis. We included statistically significant risk factors, sex, and age in the final models. All analyses were conducted with R software. P values < 0.05 were considered statistically significant.

AUTHOR CONTRIBUTIONS

Mingming Jin, Xuyuan Huang, Yuxin Shi and Gang Huang conducted the study design. Nannan Shi, Meng Wang, Chunzi Shi and Shengjie Lu carried out the assays and collected the samples. Qing Chang, Shuang Sha, Yun Lin and Yingmin Chen performed the statistical analysis. Hui Zhou and Kaiyi Liang participated the coordination of research and worked as technical consultants. Mingming Jin drafted the manuscript. All authors reviewed and approved the final manuscript.

CONFLICTS OF INTEREST

These authors declare no conflicts of interest.

FUNDING

This project was supported by the Key Program of National Natural Science Foundation of China (Grant No.81830052, 81530053), Construction project of Shanghai Key Laboratory of Molecular Imaging (18DZ2260400), Shanghai Municipal Education Commission (Class II Plateau Disciplinary Construction Program of Medical Technology of SUMHS, 2018-2020).

REFERENCES

1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, et al, and China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020; 382:727–33.
   https://doi.org/10.1056/NEJMoa2001017
   PMID:31978945

2. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020; 109:102433.
   https://doi.org/10.1016/j.jaut.2020.102433
   PMID:32113704

3. Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W, Li J, Zhao D, Xu D, Gong Q, Liao J, Yang H, Hou W, Zhang Y. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine
pregnant women: a retrospective review of medical records. Lancet. 2020; 395:809–15. 
https://doi.org/10.1016/S0140-6736(20)30360-3
PMID: 32151335

4. Pan L, Wang L, Huang X. How to face the novel coronavirus infection during the 2019-2020 epidemic: the experience of sichuan provincial people’s hospital. Intensive Care Med. 2020; 46:573–75.
https://doi.org/10.1007/s00134-020-05964-0
PMID: 32072300

5. Khot WY, Nadkar MY. The 2019 novel coronavirus outbreak – a global threat. J Assoc Physicians India. 2020; 68:67–71.
PMID: 32138488

6. Cao X. COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol. 2020; 20:269–70.
https://doi.org/10.1038/s41577-020-0308-3
PMID: 32273594

7. Xu X, Chen P, Wang J, Feng J, Zhou H, Li X, Zhong W, Hao P. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci. 2020; 63:457–60.
https://doi.org/10.1007/s11427-020-1637-5
PMID: 32009228

8. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, Chen HD, Chen J, Luo Y, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579:270–73.
https://doi.org/10.1038/s41586-020-2012-7
PMID: 32015507

9. Wang J, Du G. COVID-19 may transmit through aerosol. Ir J Med Sci. 2020; 189:1143-44.
https://doi.org/10.1007/s11845-020-02218-2
PMID: 32212099

10. Gao X, Yuan Z, Yang D, Li H, Zhang Y, Gao P, Liu X, Zhao W, Xiao T, Duan X. A family cluster of severe acute respiratory syndrome coronavirus 2 infections. Eur J Clin Microbiol Infect Dis. 2020; 39:1611–15.
https://doi.org/10.1007/s10096-020-03881-0
PMID: 32270413

11. Zwald ML, Lin W, Sondermeyer Cookey GL, Weiss C, Suarez A, Fischer M, Bonin BJ, Jain S, Langley GE, Park BJ, Moula D, Benedict R, Nguyen N, Han GS. Rapid sentinel surveillance for COVID-19 - Santa Clara county, California, March 2020. MMWR Morb Mortal Wkly Rep. 2020; 69:419–21.
https://doi.org/10.15585/mmwr.mm6914e3
PMID: 32271724

12. Zhou Y, Zhang Z, Tian J, Xiong S. Risk factors associated with disease progression in a cohort of patients infected with the 2019 novel coronavirus. Ann Palliat Med. 2020; 9:428–36.
https://doi.org/10.21037/apm.2020.03.26
PMID: 32233642

13. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, Zhang Y, Song J, Wang S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020; 180:1–11.
https://doi.org/10.1001/jamainternmed.2020.0994
PMID: 32167524

14. Sadighi Akha AA. Aging and the immune system: an overview. J Immunol Methods. 2018; 463:21–26.
https://doi.org/10.1016/j.jim.2018.08.005
PMID: 30114401

15. Pawelec G, Weng NP. Can an effective SARS-CoV-2 vaccine be developed for the older population? Immun Ageing. 2020; 17:8.
https://doi.org/10.1186/s12979-020-00180-2
PMID: 32300370

16. Wang L. C-reactive protein levels in the early stage of COVID-19. Med Mal Infect. 2020; 50:332–34.
https://doi.org/10.1016/j.medmal.2020.03.007
PMID: 32243911

17. Mahallawi WH, Khabour OF, Zhang Q, Makhdoom HM, Suliman BA. MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile. Cytokine. 2018; 103:8–13.
https://doi.org/10.1016/j.cytto.2018.01.025
PMID: 29414327

18. Wong CK, Lam CW, Wu AK, Ip WK, Lee NL, Chan IH, Lit LC, Hui DS, Chan MH, Chung SS, Sung JJ. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol. 2004; 136:95–103.
https://doi.org/10.1111/j.1365-2249.2004.02415.x
PMID: 15030519

19. Lagunas-Rangel FA, Chávez-Valencia V. High IL-6/IFN-γ ratio could be associated with severe disease in COVID-19 patients. J Med Virol. 2020; 10:1002.
https://doi.org/10.1002/jmv.25900
PMID: 32297995

20. Liu B, Li M, Zhou Z, Guan X, Xiang Y. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? J Autoimmun. 2020; 111:102452.
https://doi.org/10.1016/j.jaut.2020.102452
PMID: 32291137

21. Fisicaro P, Boni C, Barili V, Laccabue D, Ferrari C. Strategies to overcome HBV-specific T cell exhaustion:
checkpoint inhibitors and metabolic re-programming. Curr Opin Virol. 2018; 30:1–8. https://doi.org/10.1016/j.coviro.2018.01.003 PMID:29414066

22. Rheinländer A, Schraven B, Bommhardt U. CD45 in human physiology and clinical medicine. Immunol Lett. 2018; 196:22–32. https://doi.org/10.1016/j.imlet.2018.01.009 PMID:29366662

23. Altin JG, Sloan EK. The role of CD45 and CD45-associated molecules in T cell activation. Immunol Cell Biol. 1997; 75:430–45. https://doi.org/10.1038/icb.1997.68 PMID:9429890

24. Hermiston ML, Xu Z, Weiss A. CD45: a critical regulator of signaling thresholds in immune cells. Annu Rev Immunol. 2003; 21:107–37. https://doi.org/10.1146/annurev.immunol.21.120601.140946 PMID:12414720

25. Trifonova RT, Bollman B, Barteneva NS, Lieberman J. Myeloid cells in intact human cervical explants capture HIV and can transmit it to CD4 T cells. Front Immunol. 2018; 9:2719. https://doi.org/10.3389/fimmu.2018.02719 PMID:30532754

26. Andersen AH, Nielsen SS, Olesen R, Mack K, Dagnæs-Hansen F, Uldbjerg N, Østergaard L, Søgaard OS, Denton PW, Tolstrup M. Humanized NOG mice for intravaginal HIV exposure and treatment of HIV infection. J Vis Exp. 2020; 155:e60723. https://doi.org/10.3791/60723 PMID:32065160

27. Krummey SM, Morris AB, Jacobs JR, McGuire DJ, Ando S, Tong KP, Zhang W, Robertson J, Guasch SA, Araki K, Larsen CP, Evavold BD, Kissick HT, Ford ML. CD45RB status of CD8^+ T cell memory defines T cell receptor affinity and persistence. Cell Rep. 2020; 30:1282–91.e5. https://doi.org/10.1016/j.celrep.2020.01.016 PMID:32023448

28. Kim ES, Chin BS, Kang CK, Kim NJ, Kang YM, Choi JP, Oh DH, Kim JH, Koh B, Kim SE, Yun NR, Lee JH, Kim JY, et al, and Korea National Committee for Clinical Management of COVID-19. Clinical course and outcomes of patients with severe acute respiratory syndrome coronavirus 2 infection: a preliminary report of the first 28 patients from the Korean cohort study on COVID-19. J Korean Med Sci. 2020; 35:e142. https://doi.org/10.3346/jkms.2020.35.e142 PMID:32242348

29. Qian ZP, Mei X, Zhang YY, Zou Y, Zhang ZG, Zhu H, Guo HY, Liu Y, Ling Y, Zhang XY, Wang JF, Lu HZ. [Analysis of baseline liver biochemical parameters in 324 cases with novel coronavirus pneumonia in Shanghai area]. Zhonghua Gan Zang Bing Za Zhi. 2020; 28:229–33. https://doi.org/10.3760/cma.j.cn501113-20200229-00076 PMID:32270660

30. Li M, Chen L, Zhang J, Xiong C, Li X. The SARS-CoV-2 receptor ACE2 expression of maternal-fetal interface and fetal organs by single-cell transcriptome study. PLoS One. 2020; 15:e0230295. https://doi.org/10.1371/journal.pone.0230295 PMID:32298273

31. Fernández-Ruiz M, Andrés A, Loinaz C, Delgado JF, López-Medrano F, San Juan R, González E, Polanco N, Folgueira MD, Lalueza A, Lumbreras C, Aguado JM. COVID-19 in solid organ transplant recipients: a single-center case series from Spain. Am J Transplant. 2020; 20:1849–58. https://doi.org/10.1111/ajt.15929 PMID:32301155